|
Background
|
Function：Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor (PubMed:35767951).
Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity (By similarity).
Interacts with CLEC10A at a Human (P08575) has 8 isomers: P08575-3, P08575-4, P08575-5, P08575-6, P08575-7, P08575-8, P08575-9, and P08575-10, with predicted values of 135-148 kDa.
Heavily N- and O-glycosylated. Interacts with CLEC10A Unmodified Supplied in PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
HY-P84134 白细胞介素-7 受体。也可作为胸腺基质淋巴细胞生成素 (TSLP) 的受体。 细胞膜；单次跨膜 I 型膜蛋白；细胞膜；单次跨膜 I 型膜蛋白；分泌型 P16871 有 4 种异构体：P16871-1：51579 Da (预测值)；P16871-2：34018 Da (预测值)；P16871-3：29936 Da (预测值)；P16871-4：28722 Da (预测值)。
N-糖基化的 IL-7Rα 与 IL-7 的结合力比未糖基化形式强 300 倍；被 MARCHF8 泛素化；导致溶酶体降解 IL-7 受体是由 IL-7R 和 IL-2RG 组成的异二聚体。TSLP 受体是由 CRLF2 和 IL-7R 组成的异二聚体。与 CD53 相互作用 (PubMed:31748347)。 Cell membrane; Single-pass type I membrane protein; Cell membrane; Single-pass type I membrane protein; Secreted Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP) P16871 has 4 isomers: P16871-1: 51579 Da (predicted); P16871-2: 34018 Da (predicted); P16871-3: 29936 Da (predicted); P16871-4: 28722 Da (predicted).
N-glycosylated IL-7Ralpha binds IL7 300-fold more tightly than the unglycosylated form;Ubiquitinated by MARCHF8; leading to lysosomal degradation The IL7 receptor is a heterodimer of IL7R and IL2RG. The TSLP receptor is a heterodimer of CRLF2 and IL7R. Interacts with CD53 (PubMed:31748347) Unmodified Supplied in PBS with 0.05% sodium azide
HY-P84151 钙依赖性细胞黏附蛋白；优先通过与另一细胞的 CDH2 链二聚化介导同型细胞间黏附。因此，钙黏蛋白可能有助于异质细胞类型的分选。在成年室管膜下区，钙黏蛋白通过介导神经干细胞与室管膜细胞的锚定来调节神经干细胞的静止状态：MMP24 切割后，CDH2 介导的锚定受到影响，从而调节神经干细胞的静止状态。在胰岛β细胞和神经嵴干细胞 (NCS 细胞) 之间的细胞间连接形成中发挥作用，促进 NCS 细胞形成突起 (基于相似性)。是神经突正常分支所必需的。是突触前和突触后组织所必需的 (基于相似性)。CDH2 可能参与神经元识别机制。在海马神经元中，可能调节树突棘密度。 细胞膜；单次跨膜 I 型膜蛋白；肌膜；细胞连接；细胞表面；桥粒；黏着连接 P19022 有两种异构体：P19022-1：99809 Da (预测值)；P19022-2：97040 Da (预测值)。
P19022 可被 MMP24 切割。胞外结构域的切割产生一个可溶性的 90 kDa N 端片段和一个 45 kDa 的膜结合 C 端片段 1 (CTF1)，后者可被 γ-分泌酶进一步切割成一个 35 kDa 的片段 (基于相似性推测)。MMP24 在神经干细胞中的切割会影响 CDH2 介导的神经干细胞与成年室管膜下区室管膜细胞的锚定，从而调节神经干细胞的静止状态 (基于相似性推测)；可能被 OBSCN 磷酸化。 同源二聚体 (通过胞外区)。也可与其他钙黏蛋白形成异源二聚体 (通过胞外区)。二聚化发生在反式，即与来自其他细胞的钙黏蛋白链相互作用 (基于相似性)。与 CDCP1 相互作用 (PubMed：16007225)。与 PCDH8 相互作用；该复合物可能也包含 TAOK2 (基于相似性)。与 PCDH8 的相互作用可能导致通过 TAOK2/p38 MAPK 通路的内吞作用 (基于相似性)。在包含 FGFR4、NCAM1、CDH2、PLCG1、FRS2、SRC、SHC1、GAP43 和 CTTN 的复合物中发现。可能与 OBSCN 相互作用 (通过蛋白激酶结构域 2)(基于相似性)。与 FBXO45 相互作用 (PubMed：32341084)。 Cell membrane; Single-pass type I membrane protein; Cell membrane, sarcolemma; Cell junction; Cell surface; Cell junction, desmosome; Cell junction, adherens junction Calcium-dependent cell adhesion protein; preferentially mediates homotypic cell-cell adhesion by dimerization with a CDH2 chain from another cell. Cadherins may thus contribute to the sorting of heterogeneous cell types. Acts as a regulator of neural stem cells quiescence by mediating anchorage of neural stem cells to ependymocytes in the adult subependymal zone: upon cleavage by MMP24, CDH2-mediated anchorage is affected, leading to modulate neural stem cell quiescence. Plays a role in cell-to-cell junction formation between pancreatic beta cells and neural crest stem (NCS) cells, promoting the formation of processes by NCS cells (By similarity). Required for proper neurite branching. Required for pre- and postsynaptic organization (By similarity). CDH2 may be involved in neuronal recognition mechanism. In hippocampal neurons, may regulate dendritic spine density P19022 has 2 isomers: P19022-1: 99809 Da (predicted); P19022-2: 97040 Da (predicted).
Cleaved by MMP24. Ectodomain cleavage leads to the generation of a soluble 90 kDa N-terminal soluble fragment and a 45 kDa membrane-bound C-terminal fragment 1 (CTF1), which is further cleaved by gamma-secretase into a 35 kDa (By similarity). Cleavage in neural stem cells by MMP24 affects CDH2-mediated anchorage of neural stem cells to ependymocytes in the adult subependymal zone, leading to modulate neural stem cell quiescence (By similarity);May be phosphorylated by OBSCN Homodimer (via extracellular region). Can also form heterodimers with other cadherins (via extracellular region). Dimerization occurs in trans, i.e. with a cadherin chain from another cell (By similarity). Interacts with CDCP1 (PubMed:16007225). Interacts with PCDH8; this complex may also include TAOK2 (By similarity). The interaction with PCDH8 may lead to internalization through TAOK2/p38 MAPK pathway (By similarity). Identified in a complex containing FGFR4, NCAM1, CDH2, PLCG1, FRS2, SRC, SHC1, GAP43 and CTTN. May interact with OBSCN (via protein kinase domain 2) (By similarity). Interacts with FBXO45 (PubMed:32341084) Unmodified Supplied in PBS with 0.05% sodium azide.
HY-P84152 是四跨膜蛋白富集微区 (TERMs) 这一特殊膜微结构域的结构成分，TERMs 作为受体聚集和信号传导的平台 (PubMed:27180357, PubMed:36078095)。因此，它参与多种生物学功能，例如细胞信号转导、迁移和蛋白质运输 (PubMed:25761241)。通过将 ADAM17 募集到四跨膜蛋白富集微区 (TEMs)，促进 ADAM17 介导的 TNF-α加工 (PubMed:36078095)。与 RICTOR 和整合素α3/ITGA3 形成复合物，介导 mTORC2 激活和 AKT1 磷酸化，从而导致细胞迁移 (PubMed:25761241)。通过与 mTOR 和 RICTOR 形成复合物，减少高葡萄糖水平诱导的细胞凋亡和自噬 (PubMed:35904232)。有助于维持肠道上皮屏障，并通过将干扰素γ受体 1/IFNGR1 的内吞途径从网格蛋白依赖性途径转变为脂筏依赖性途径，从而限制 STAT1 的激活强度和持续时间，在肠道炎症的调节中发挥作用 (PubMed:37204469)。通过与内皮素转化酶 ECE1 结合并调节其将内皮素-1 前体转化为内皮素的活性，发挥内皮素轴的调节作用 (PubMed:37835445)。 细胞膜；多通道膜蛋白
组织特异性：胃癌、结肠癌、直肠癌和胰腺癌 形成同源寡聚体 (PubMed:34524408)。与 MEP1B 相互作用 (PubMed:27180357)。与整合素 α3/ITGA3 相互作用 (PubMed:25761241)。与 RICTOR 和 MTOR 相互作用 (PubMed:25761241, PubMed:35904232)。与 ADAM17 相互作用 (PubMed:36078095)。与 ECE1 相互作用 (PubMed:37835445)。 Cell membrane; Multi-pass membrane protein
Tissue_specificity:Gastric, colon, rectal, and pancreatic carcinomas
Structural component of specialized membrane microdomains known as tetraspanin-enriched microdomains (TERMs), which act as platforms for receptor clustering and signaling (PubMed:27180357, PubMed:36078095). Participates thereby in diverse biological functions such as cell signal transduction, migration and protein trafficking (PubMed:25761241). Promotes ADAM17-mediated TNF-alpha processing through recruitment of ADAM17 to tetraspanin-enriched micro-domains (TEMs) (PubMed:36078095). Forms a complex with RICTOR and integrin alpha3/ITGA3 to mediate mTORC2 activation and AKT1 phosphorylation leading to cell migration (PubMed:25761241). Reduces apoptosis and autophagy induced by high glucose levels through forming a complex with mTOR and RICTOR (PubMed:35904232). Contributes to the maintenance of intestinal epithelial barrier and plays a role in the regulation of intestine inflammation by switching interferon gamma receptor 1/IFNGR1 from clathrin-dependent to lipid raft-dependent endocytosis route to limit STAT1 activation magnitude and duration (PubMed:37204469). Acts as a modulator of the endothelin axis by associating with endothelin converting enzyme ECE1 and regulating its activity of conversion of the endothelin-1 precursor to endothelin (PubMed:37835445) Forms homooligomers (PubMed:34524408). Interacts with MEP1B (PubMed:27180357). Interacts with integrin alpha3/ITGA3 (PubMed:25761241). Interacts with RICTOR and MTOR (PubMed:25761241, PubMed:35904232). Interacts with ADAM17 (PubMed:36078095). Interacts with ECE1 (PubMed:37835445) Unmodified Supplied in PBS with 0.05% sodium azide
HY-P86786 参与染色质重塑 (改变 DNA-核小体拓扑结构) 介导的特定基因的转录激活和抑制。它是 SWI/SNF 染色质重塑复合物的组成部分，该复合物执行关键的酶促活性，以 ATP 依赖的方式改变核小体内的 DNA-组蛋白接触，从而改变染色质结构 (PubMed:11018012)。它可以刺激这些复合物催化亚基的 ATPase 活性 (PubMed:10078207)。它可能参与非神经元细胞中 CoREST 依赖的神经元特异性基因启动子抑制 (PubMed:12192000)。它属于神经祖细胞特异性染色质重塑复合物 (npBAF 复合物) 和神经元特异性染色质重塑复合物 (nBAF 复合物)。在神经发育过程中，当神经元退出细胞周期并分化为成体状态时，其染色质重塑机制会从干细胞/祖细胞转变为有丝分裂后细胞。从增殖的神经干细胞/祖细胞到有丝分裂后神经元的转变需要 npBAF 和 nBAF 复合物亚基组成的变化。当神经祖细胞退出有丝分裂并分化为神经元时，含有 ACTL6A/BAF53A 和 PHF10/BAF45A 的 npBAF 复合物会被神经元特异性复合物 (nBAF) 中同源的替代亚基 ACTL6B/BAF53B 和 DPF1/BAF45B 或 DPF3/BAF45C 所取代。npBAF 复合物对于多能神经干细胞的自我更新/增殖能力至关重要。nBAF 复合物与 CREST 共同调控树突生长必需基因的活性 (基于相似性)。髓系分化的关键调节因子，控制粒细胞生成和参与中性粒细胞颗粒形成的基因表达 (基于相似性) 核
组织特异性：普遍表达
阳性样本：K-562 cell lysate, A431 cell lysate, MCF7 cell lysate, HeLa cell lysate, SW620 cell lysate, SW680 cell lysate, PANC cell lysate, C2C12 cell lysate, NIH/3T3 cell lysate, Neur
Q8TAQ2 有 3 种异构体：Q8TAQ2-1：132879 Da (预测值)；Q8TAQ2-2：124841 Da (预测值)；Q8TAQ2-3：126924 Da (预测值)。
SIRT6 对 Lys-312 的单 ADP 核糖基化促进其募集至血红素加氧酶-1 (HO-1) 基因座的增强子区域，从而激活该基因座的转录。 SWI/SNF 复合物是多蛋白染色质重塑复合物的组成部分，包括 SWI/SNF-A (BAF)、SWI/SNF-B (PBAF) 及相关复合物。典型的 SWI/SNF 复合物包含一个催化亚基 (SMARCA4/BRG1/BAF190A 或 SMARCA2/BRM/BAF190B) 以及至少 SMARCE1、ACTL6A/BAF53、SMARCC1/BAF155、SMARCC2/BAF170 和 SMARCB1/SNF5/BAF47。此外，每个复合物可能还包含其他特异性亚基，从而在发育和组织上形成多种可能的组合 (可能)。 BAF 复合物的组成部分至少包括肌动蛋白 (ACTB)、ARID1A/BAF250A、ARID1B/BAF250B、SMARCA2/BRM、SMARCA4/BRG1、ACTL6A/BAF53、ACTL6B/BAF53B、SMARCE1/BAF57、SMARCC1/BAF155、SMARCC2/BAF170、SMARCB1/SNF5/INI1，以及一个或多个 SMARCD1/BAF60A、SMARCD2/BAF60B 或 SMARCD3/BAF60C。在肌肉细胞中，BAF 复合物还包含 DPF3 (PubMed:18765789)。神经祖细胞特异性染色质重塑复合物 (npBAF 复合物) 的组成部分，至少由以下分子组成：ARID1A/BAF250A 或 ARID1B/BAF250B、SMARCD1/BAF60A、SMARCD3/BAF60C、SMARCA2/BRM/BAF190B、SMARCA4/BRG1/BAF190A、SMARCB1/BAF47、SMARCC1/BAF155、SMARCE1/BAF57、SMARCC2/BAF170、PHF10/BAF45A、ACTL6A/BAF53A 和肌动蛋白。神经元特异性染色质重塑复合物 (nBAF 复合物) 的组成部分，至少包括：ARID1A/BAF250A 或 ARID1B/BAF250B、SMARCD1/BAF60A、SMARCD3/BAF60C、SMARCA2/BRM/BAF190B、SMARCA4/BRG1/BAF190A、SMARCB1/BAF47、SMARCC1/BAF155、SMARCE1/BAF57、SMARCC2/BAF170、DPF1/BAF45B、DPF3/BAF45C、ACTL6B/BAF53B 和肌动蛋白。 SWI/SNF-B (PBAF) 染色质重塑复合物的组成部分，至少由 SMARCA4/BRG1、SMARCB1/BAF47/SNF5、ACTL6A/BAF53A 或 ACTL6B/BAF53B、SMARCE1/BAF57、SMARCD1/BAF60A、SMARCD2/BAF60B、可能还有 SMARCD3/BAF60C、SMARCC1/BAF155、SMARCC2/BAF170、PBRM1/BAF180、ARID2/BAF200 和肌动蛋白组成 (PubMed:22952240，PubMed:26601204)。可能与 SMARCA2 和 SMARCA4 协同作用，与 SIN3A 组蛋白去乙酰化酶转录抑制复合物相互作用 (PubMed:11238380)。与 SMARD1 相互作用 (PubMed:12917342)。与 KDM6B 相互作用 (基于序列相似性)。与 RCOR1 相互作用 (PubMed:12192000)。与 DPF2 相互作用 (PubMed:28533407)。与 ERCC6 相互作用 (PubMed:24874740)。与 FOS 相互作用 (基于序列相似性)。 Nucleus
Tissue_specificity:Ubiquitously expressed
Positive sample: K-562 cell lysate, A431 cell lysate, MCF7 cell lysate, HeLa cell lysate, SW620 cell lysate, SW680 cell lysate, PANC cell lysate, C2C12 cell lysate, NIH/3T3 cell lysate, Neur
Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner (PubMed:11018012). Can stimulate the ATPase activity of the catalytic subunit of these complexes (PubMed:10078207). May be required for CoREST dependent repression of neuronal specific gene promoters in non-neuronal cells (PubMed:12192000). Belongs to the neural progenitors-specific chromatin remodeling complex (npBAF complex) and the neuron-specific chromatin remodeling complex (nBAF complex). During neural development a switch from a stem/progenitor to a postmitotic chromatin remodeling mechanism occurs as neurons exit the cell cycle and become committed to their adult state. The transition from proliferating neural stem/progenitor cells to postmitotic neurons requires a switch in subunit composition of the npBAF and nBAF complexes. As neural progenitors exit mitosis and differentiate into neurons, npBAF complexes which contain ACTL6A/BAF53A and PHF10/BAF45A, are exchanged for homologous alternative ACTL6B/BAF53B and DPF1/BAF45B or DPF3/BAF45C subunits in neuron-specific complexes (nBAF). The npBAF complex is essential for the self-renewal/proliferative capacity of the multipotent neural stem cells. The nBAF complex along with CREST plays a role regulating the activity of genes essential for dendrite growth (By similarity). Critical regulator of myeloid differentiation, controlling granulocytopoiesis and the expression of genes involved in neutrophil granule formation (By similarity) Q8TAQ2 has 3 isomers: Q8TAQ2-1: 132879 Da (predicted); Q8TAQ2-2: 124841 Da (predicted); Q8TAQ2-3: 126924 Da (predicted).
Mono-ADP-ribosylation at Lys-312 by SIRT6 promotes recruitment to the enhancer region of the Heme oxygenase-1 (HO-1) locus, leading to transcription activation of the locus Component of the multiprotein chromatin-remodeling complexes SWI/SNF: SWI/SNF-A (BAF), SWI/SNF-B (PBAF) and related complexes. The canonical complex contains a catalytic subunit (either SMARCA4/BRG1/BAF190A or SMARCA2/BRM/BAF190B) and at least SMARCE1, ACTL6A/BAF53, SMARCC1/BAF155, SMARCC2/BAF170, and SMARCB1/SNF5/BAF47. Other subunits specific to each of the complexes may also be present permitting several possible combinations developmentally and tissue specific (Probable). Component of the BAF complex, which includes at least actin (ACTB), ARID1A/BAF250A, ARID1B/BAF250B, SMARCA2/BRM, SMARCA4/BRG1, ACTL6A/BAF53, ACTL6B/BAF53B, SMARCE1/BAF57, SMARCC1/BAF155, SMARCC2/BAF170, SMARCB1/SNF5/INI1, and one or more SMARCD1/BAF60A, SMARCD2/BAF60B, or SMARCD3/BAF60C. In muscle cells, the BAF complex also contains DPF3 (PubMed:18765789). Component of neural progenitors-specific chromatin remodeling complex (npBAF complex) composed of at least, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, PHF10/BAF45A, ACTL6A/BAF53A and actin. Component of neuron-specific chromatin remodeling complex (nBAF complex) composed of at least, ARID1A/BAF250A or ARID1B/BAF250B, SMARCD1/BAF60A, SMARCD3/BAF60C, SMARCA2/BRM/BAF190B, SMARCA4/BRG1/BAF190A, SMARCB1/BAF47, SMARCC1/BAF155, SMARCE1/BAF57, SMARCC2/BAF170, DPF1/BAF45B, DPF3/BAF45C, ACTL6B/BAF53B and actin. Component of the SWI/SNF-B (PBAF) chromatin remodeling complex, at least composed of SMARCA4/BRG1, SMARCB1/BAF47/SNF5, ACTL6A/BAF53A or ACTL6B/BAF53B, SMARCE1/BAF57, SMARCD1/BAF60A, SMARCD2/BAF60B, perhaps SMARCD3/BAF60C, SMARCC1/BAF155, SMARCC2/BAF170, PBRM1/BAF180, ARID2/BAF200 and actin (PubMed:22952240, PubMed:26601204). May also interact with the SIN3A histone deacetylase transcription repressor complex in conjunction with SMARCA2 and SMARCA4 (PubMed:11238380). Interacts with SMARD1 (PubMed:12917342). Interacts with KDM6B (By similarity). Interaction with RCOR1 (PubMed:12192000). Interacts with DPF2 (PubMed:28533407). Interacts with ERCC6 (PubMed:24874740). Interacts with FOS (By similarity) Unmodified Supplied in PBS (pH7.4), 0.1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide. Nucleus.
HY-P84165 TFIID 基础转录因子复合物在 RNA 聚合酶 II (Pol II) 依赖性转录的起始过程中起着重要作用 (PubMed:33795473)。TFIID 通过其亚基 TBP (一种 TATA 盒结合蛋白) 识别并结合含有或不含 TATA 盒的启动子，并促进前起始复合物 (PIC) 的组装 (PubMed:2194289, PubMed:2363050, PubMed:2374612, PubMed:27193682, PubMed:33795473)。 TFIID 复合物由 TBP 及其相关因子 (TAF) 组成，包括 TAF1、TAF2、TAF3、TAF4、TAF5、TAF6、TAF7、TAF8、TAF9、TAF10、TAF11、TAF12 和 TAF13 (PubMed:27007846, PubMed:33795473)。TFIID 复合物的结构可分为三个模块：TFIID-A、TFIID-B 和 TFIID-C (PubMed:33795473)。TBP 与 TAF3 和 TAF5 共同构成 TFIID-A 模块 (PubMed:33795473)。 TBP 是一种通用转录因子，在 TFIID 复合物的核心发挥作用 (PubMed:2194289, PubMed:2363050, PubMed:2374612, PubMed:27193682, PubMed:33795473, PubMed:9836642)。在启动子上组装核心 PIC 时，作为 TFIID 的一部分，TBP 会结合并弯曲启动子 DNA，而与启动子是否含有 TATA 盒无关 (PubMed:33795473)。TBP 也是包含 BRF2 的转录因子复合物的组成部分，该复合物调控 RNA 聚合酶 III 介导的转录 (PubMed:26638071)。 SL1/TIF-IB 复合物是转录因子 SL1 的组成部分，该复合物参与 RNA 聚合酶 I 依赖性转录过程中前起始复合物 (PIC) 的组装 (PubMed:15970593)。PIC 的形成速率可能主要取决于 SL1 与 rDNA 启动子的结合速率 (PubMed:15970593)。SL1 还参与 rDNA 上核仁转录因子 1/UBTF 的稳定 (PubMed:15970593)。 核
组织特异性：广泛表达，在睾丸和卵巢中含量最高。 P20226 有 2 个异构体：P20226-1：37698 Da (预测)；P20226-2：35657 Da (预测)。 以单体形式结合 DNA (PubMed:2194289, PubMed:2374612)。TFIID 基础转录因子复合物的组成部分，该复合物由 TATA 盒结合蛋白 TBP 和多个 TBP 相关因子 (TAF) 组成，包括 TAF1、TAF2、TAF3、TAF4、TAF5、TAF6、TAF7、TAF8、TAF9、TAF10、TAF11、TAF12 和 TAF13 (PubMed:27007846, PubMed:33795473, PubMed:9836642)。含有 TFIID 的 RNA 聚合酶 II 起始前复合物的一部分，由 TBP 和至少 GTF2A1、GTF2A2、GTF2E1、GTF2E2、GTF2F1、GTF2H2、GTF2H3、GTF2H4、GTF2H5、GTF2B、TCEA1、ERCC2、ERCC3、TAF1、TAF2、TAF3、TAF4、TAF5、TAF6、TAF7、TAF8、TAF9、TAF10、TAF11、TAF12 和 TAF13 组成 (PubMed:27007846、PubMed:27193682、PubMed:33795473)。转录因子 SL1/TIF-IB 复合物的组成部分，由 TBP 和至少 TAF1A、TAF1B、TAF1C 和 TAF1D 组成 (PubMed:7801123)。TBP 与 TFIID 或 SL1/TIF-IB 的结合似乎是互斥的 (PubMed:7801123)。与 TAF1A、TAF1B 和 TAF1C 相互作用 (PubMed:7801123)。与 TFIIB、NCOA6、DRAP1、DR1 和 ELF3 相互作用 (PubMed:10391676, PubMed:10567404, PubMed:11461703)。与 SPIB、SNAPC1、SNAPC2 和 SNAPC4 相互作用 (PubMed:10196196, PubMed:12621023)。与 UTF1 相互作用 (PubMed:9748258)。与 BRF2 相互作用；这种相互作用促进 BRF2 募集到含有 TATA 盒的启动子 (PubMed:11564744, PubMed:26638071)。与 UBTFD 相互作用 (PubMed:7982918)。与 GPBP1D 相互作用 (基于相似性)。与 CITED2 相互作用 (基于相似性)。与 ATF7IP 相互作用 (可能)。与 LLPH 相互作用 (基于相似性)。与 HSF1 相互作用 (通过转录激活结构域)(PubMed:11005381)。与 GTF2B 相互作用 (通过 C 端)；这种与启动子结合的 TBP 的相互作用引导 RNA 聚合酶 II 进入起始前复合物 (PIC)(PubMed:8504927)。与 PAX5 相互作用 (PubMed：10197586)。与 MSX1 相互作用；该相互作用可能抑制 MSX1 的自身失活 (基于相似性)。 Nucleus
Tissue_specificity:It is widely expressed, with the highest concentrations in the testes and ovaries.
The TFIID basal transcription factor complex plays a major role in the initiation of RNA polymerase II (Pol II)-dependent transcription (PubMed:33795473). TFIID recognizes and binds promoters with or without a TATA box via its subunit TBP, a TATA-box-binding protein, and promotes assembly of the pre-initiation complex (PIC) (PubMed:2194289, PubMed:2363050, PubMed:2374612, PubMed:27193682, PubMed:33795473). The TFIID complex consists of TBP and TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:27007846, PubMed:33795473). The TFIID complex structure can be divided into 3 modules TFIID-A, TFIID-B, and TFIID-C (PubMed:33795473). TBP forms the TFIID-A module together with TAF3 and TAF5 (PubMed:33795473). TBP is a general transcription factor that functions at the core of the TFIID complex (PubMed:2194289, PubMed:2363050, PubMed:2374612, PubMed:27193682, PubMed:33795473, PubMed:9836642). During assembly of the core PIC on the promoter, as part of TFIID, TBP binds to and also bends promoter DNA, irrespective of whether the promoter contains a TATA box (PubMed:33795473). Component of a BRF2-containing transcription factor complex that regulates transcription mediated by RNA polymerase III (PubMed:26638071). Component of the transcription factor SL1/TIF-IB complex, which is involved in the assembly of the PIC during RNA polymerase I-dependent transcription (PubMed:15970593). The rate of PIC formation probably is primarily dependent on the rate of association of SL1 with the rDNA promoter (PubMed:15970593). SL1 is involved in stabilization of nucleolar transcription factor 1/UBTF on rDNA (PubMed:15970593) P20226 has 2 isomers: P20226-1: 37698 Da (predicted); P20226-2: 35657 Da (predicted). Binds DNA as monomer (PubMed:2194289, PubMed:2374612). Component of the TFIID basal transcription factor complex, composed of TATA-box-binding protein TBP, and a number of TBP-associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:27007846, PubMed:33795473, PubMed:9836642). Part of a TFIID-containing RNA polymerase II pre-initiation complex that is composed of TBP and at least GTF2A1, GTF2A2, GTF2E1, GTF2E2, GTF2F1, GTF2H2, GTF2H3, GTF2H4, GTF2H5, GTF2B, TCEA1, ERCC2, ERCC3, TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:27007846, PubMed:27193682, PubMed:33795473). Component of the transcription factor SL1/TIF-IB complex, composed of TBP and at least TAF1A, TAF1B, TAF1C and TAF1D (PubMed:7801123). Association of TBP to form either TFIID or SL1/TIF-IB appears to be mutually exclusive (PubMed:7801123). Interacts with TAF1A, TAF1B and TAF1C (PubMed:7801123). Interacts with TFIIB, NCOA6, DRAP1, DR1 and ELF3 (PubMed:10391676, PubMed:10567404, PubMed:11461703). Interacts with SPIB, SNAPC1, SNAPC2 and SNAPC4 (PubMed:10196196, PubMed:12621023). Interacts with UTF1 (PubMed:9748258). Interacts with BRF2; this interaction promotes recruitment of BRF2 to TATA box-containing promoters (PubMed:11564744, PubMed:26638071). Interacts with UBTFD (PubMed:7982918). Interacts with GPBP1D (By similarity). Interacts with CITED2 (By similarity). Interacts with ATF7IP (Probable). Interacts with LLPH (By similarity). Interacts with HSF1 (via transactivation domain) (PubMed:11005381). Interacts with GTF2B (via C-terminus); this interaction with promoter-bound TBP guides RNA polymerase II into the pre-initiation complex (PIC) (PubMed:8504927). Interacts with PAX5 (PubMed:10197586). Interacts with MSX1; the interaction may inhibit MSX1 autoinactivation (By similarity) Unmodified Supplied in PBS with 0.05% sodium azide
HY-P85838 细丝相关蛋白，参与平滑肌收缩的调节和调控。它能够与肌动蛋白、钙调蛋白和原肌球蛋白结合。钙调蛋白与肌动蛋白的相互作用会抑制肌动球蛋白 Mg-ATPase 活性 (基于相似性)。
组织特异性：平滑肌，以及含有大量平滑肌的组织 P51911 有 2 个异构体：P51911-1：33170 Da (预测)；P51911-2：31055 Da (预测)。 cGMP 激酶信号复合物的一部分，至少由 ACTA2/α-肌动蛋白、CNN1/钙调蛋白 H1、PLN/磷蛋白、PRKG1 和 ITPR1 组成。
Tissue_specificity:Smooth muscle, and tissues containing a large amount of smooth muscle.
Thin filament-associated protein that is implicated in the regulation and modulation of smooth muscle contraction. It is capable of binding to actin, calmodulin and tropomyosin. The interaction of calponin with actin inhibits the actomyosin Mg-ATPase activity (By similarity) P51911 has 2 isomers: P51911-1: 33170 Da (predicted); P51911-2: 31055 Da (predicted). Part of cGMP kinase signaling complex at least composed of ACTA2/alpha-actin, CNN1/calponin H1, PLN/phospholamban, PRKG1 and ITPR1 Unmodified Supplied in PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
HY-P85845 易化葡萄糖转运蛋白负责构成性或基础性葡萄糖摄取 (PubMed:10227690, PubMed:10954735, PubMed:18245775, PubMed:19449892, PubMed:25982116, PubMed:27078104, PubMed:32860739)。其底物特异性非常广泛；可转运多种醛糖，包括戊糖和己糖 (PubMed:18245775, PubMed:19449892)。它是大脑最重要的能量载体：存在于血脑屏障，确保葡萄糖以不依赖能量的方式易化转运进入大脑 (PubMed:10227690)。与 BSG 和 NXNL1 协同作用，通过增加感光细胞对葡萄糖的摄取来促进视网膜锥细胞的存活 (基于相似性)。是中内胚层分化所必需的 (基于相似性)。 细胞膜；多通道膜蛋白；黑素体；感光细胞内节
组织特异性：在红细胞中检测到 (蛋白质水平) 。在多种人体组织中表达水平不一。 通过 PDZ 结构域与 GIPC 相互作用 (基于相似性)。与 ADD2、DMTN 和 SLC2A1 形成复合物。通过 C 端胞质区与 DMTN 亚型 2 相互作用 (PubMed:18347014)。与 SNX27 相互作用；该相互作用在内吞过程中对于防止溶酶体降解和促进其循环至质膜至关重要 (PubMed:23563491)。与 STOM 相互作用 (PubMed:23219802)。通过富含谷氨酰胺的区域与 SGTA 相互作用 (基于相似性)。与 BSG 亚型 1 相互作用 (PubMed:25957687)。 Cell membrane; Multi-pass membrane protein; Melanosome; Photoreceptor inner segment
Tissue_specificity:Protein levels were detected in red blood cells. Expression levels vary in various human tissues.
Facilitative glucose transporter, which is responsible for constitutive or basal glucose uptake (PubMed:10227690, PubMed:10954735, PubMed:18245775, PubMed:19449892, PubMed:25982116, PubMed:27078104, PubMed:32860739). Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses (PubMed:18245775, PubMed:19449892). Most important energy carrier of the brain: present at the blood-brain barrier and assures the energy-independent, facilitative transport of glucose into the brain (PubMed:10227690). In association with BSG and NXNL1, promotes retinal cone survival by increasing glucose uptake into photoreceptors (By similarity). Required for mesendoderm differentiation (By similarity) Interacts with GIPC (via PDZ domain) (By similarity). Found in a complex with ADD2, DMTN and SLC2A1. Interacts (via C-terminus cytoplasmic region) with DMTN isoform 2 (PubMed:18347014). Interacts with SNX27; the interaction is required when endocytosed to prevent degradation in lysosomes and promote recycling to the plasma membrane (PubMed:23563491). Interacts with STOM (PubMed:23219802). Interacts with SGTA (via Gln-rich region) (By similarity). Interacts with isoform 1 of BSG (PubMed:25957687) Unmodified Supplied in PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
HY-P85676 白细胞介素-2 受体。该受体通过控制调节性 T 细胞 (TREGs) 的活性参与免疫耐受的调节。TREGs 抑制自身反应性 T 细胞的活化和扩增。 膜；单次跨膜 I 型膜蛋白 由α亚基和β亚基组成的非共价二聚体。IL2R 以三种不同的形式存在：高亲和力二聚体、中等亲和力单体 (β亚基) 和低亲和力单体 (α亚基)。高亲和力和中等亲和力形式还会与γ亚基结合。 Membrane; Single-pass type I membrane protein Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells Non-covalent dimer of an alpha and a beta subunit. IL2R exists in 3 different forms: a high affinity dimer, an intermediate affinity monomer (beta subunit), and a low affinity monomer (alpha subunit). The high and intermediate affinity forms also associate with a gamma subunit Unmodified Supplied in PBS, pH 7.4, containing 0.5%BSA, 0.02% sodium azide as Preservative and 50% Glycerol.
HY-P85690 Unmodified Supplied in PBS, pH 7.4, containing 0.5%BSA, 0.02% sodium azide as Preservative and 50% Glycerol.
HY-P85693 脯氨酸定向丝氨酸/苏氨酸蛋白激酶，对神经元细胞周期阻滞和分化至关重要，可能通过触发细胞周期异常再入参与神经系统疾病中的细胞凋亡。与 D1 和 D3 型 G1 期细胞周期蛋白相互作用。磷酸化 SRC、NOS3、VIM/波形蛋白、p35/CDK5R1、MEF2A、SIPA1L1、SH3GLB1、PXN、PAK1、MCAM/MUC18、SEPT5、SYN1、DNM1、AMPH、SYNJ1、CDK16、RAC1、RHOA、CDC42、TONEBP/NFAT5、MAPT/TAU、MAP1B、组蛋白 H1、p53/TP53、HDAC1、APEX1、PTK2/FAK1、亨廷顿蛋白/HTT、ATM、MAP2、NEFH 和 NEFM。通过磷酸化关键蛋白，调控多种神经元发育和生理过程，包括神经元存活、迁移和分化、轴突和神经突生长、突触发生、少突胶质细胞分化、突触可塑性和神经传递。负调控海马神经元胞体和突触末端由 CACNA1B/CAV2.2 介导的 Ca2?释放概率 (基于相似性)。与 CDK5R1 (p35) 和 CDK5R2 (p39) 相互作用激活，尤其是在有丝分裂后神经元中，并在自身刺激环路中促进 CDK5R1 (p35) 的表达。它能磷酸化许多下游底物，例如 Rho 和 Ras 家族的小 GTP 酶 (如 PAK1、RAC1、RHOA、CDC42) 或微管结合蛋白 (如 MAPT/TAU、MAP2、MAP1B)，并调节肌动蛋白动力学，从而调控神经突生长和/或棘突形态发生。此外，它还能磷酸化突触末端的胞吐相关蛋白，例如 MCAM/MUC18、SEPT5、SYN1 和 CDK16/PCTAIRE1，以及胞吞相关蛋白，例如 DNM1、AMPH 和 SYNJ1。在成熟的中枢神经系统 (CNS) 中，它通过磷酸化与神经递质释放和突触可塑性相关的底物来调节神经递质的运动，包括突触小泡胞吐、小泡与突触前膜的融合以及胞吞作用。 p53/TP53 通过激活抗凋亡蛋白 BCL2 和 STAT3，并负调控 JNK3/MAPK10 活性来促进细胞存活。基因毒性和氧化应激诱导的 p53/TP53 磷酸化可增强其稳定性，防止泛素连接酶介导的蛋白酶体降解，并诱导 p53/TP53 靶基因的转录激活，从而调控细胞凋亡。p35/CDK5R1 的磷酸化可增强其稳定性，防止钙蛋白酶介导的蛋白水解生成 p25/CDK5R1，并避免泛素连接酶介导的蛋白酶体降解。在异常的细胞周期活动和 DNA 损伤期间，p25/CDK5 活性通过失调 HDAC1 引发细胞周期活动和双链 DNA 断裂，进而导致神经元死亡。 DNA 损伤触发的亨廷顿蛋白/HTT 在神经元细胞核内的磷酸化可保护神经元免受多聚谷氨酰胺扩增以及 DNA 损伤介导的毒性作用。在少突胶质细胞 (OLs) 分化过程中，PXN 的磷酸化会降低其与基质细胞黏着斑 (MCFA) 中 PTK2/FAK1 的相互作用。PXN 是 Wnt/β-catenin 信号通路的负调控因子。它激活 GAIT (IFN-γ激活的翻译抑制因子) 通路，该通路抑制髓系细胞中促炎基因转录后调控子的表达；PXN 以 IFN-γ依赖的方式磷酸化谷氨酰-脯氨酰 tRNA 合成酶 (EPRS) 的连接域，这是 GAIT 复合物组装的初始步骤。SH3GLB1 的磷酸化是饥饿神经元中自噬诱导所必需的。渗透压应激诱导 TONEBP/NFAT5 磷酸化，进而促进其快速核定位。神经毒素诱导 MEF2 在细胞核内磷酸化失活，导致神经元凋亡。APEX1 AP 内切脱氧核糖核酸酶磷酸化抑制其活性，导致 DNA 损伤积累，最终促进神经元死亡。NOS3 磷酸化下调 NOS3 衍生的亚硝酸盐 (NO) 水平。SRC 磷酸化介导其泛素依赖性降解，进而导致细胞骨架重组。SRC 可能通过调节伪足形成来调控内皮细胞迁移和血管生成。此外，SRC 还通过介导 EFNA1-EPHA4 信号通路参与树突棘形态发生。 p35/CDK5 复合物通过调节 CLOCK 蛋白的功能参与生物钟的调控：它在 Thr-451 和 Thr-461 位点磷酸化 CLOCK 蛋白，并调节 CLOCK-BMAL1 异二聚体的转录活性，同时改变其稳定性和亚细胞分布。 细胞质；细胞核；细胞膜；外周膜蛋白；胞体；伪足；生长锥；突触后致密区；突触；细胞核
组织特异性：普遍表达 (PubMed:17009320，PubMed:19693690) 。在皮层神经元中积累 (蛋白水平) (PubMed:17009320) ；在睾丸、骨骼肌、结肠、骨髓和卵巢中表达。 Q00535 有两种异构体：Q00535-1：33304 Da (预测值)；Q00535-2：29544 Da (预测值)。
ABL1 和 FYN 对 Tyr-15 的磷酸化以及酪蛋白激酶 1 对 Ser-159 的磷酸化均能促进激酶活性。相反，Thr-14 的磷酸化会抑制活性；Ser-159 的磷酸化对于最大催化活性至关重要。 CDK5 是一种异二聚体，由催化亚基 CDK5 和调节亚基 CDK5R1 (p25) 组成；此外，它还与至少 CDK5、CDK5R1 (p35) 以及 CDK5RAP1、CDK5RAP2 或 CDK5RAP3 组成大分子复合物。只有异二聚体才具有激酶活性。在神经毒性应激和神经元损伤条件下，p35 被钙蛋白酶切割生成 p25，后者过度激活 CDK5，导致 CDK5 功能失活并通常具有毒性。CDK5 还与 CABLES1 和 ABL1 形成三分子复合物。它与 CABLES1 和 CABLES2 相互作用 (基于相似性)。此外，它还与 AATK 和 GSTP1 相互作用。当与 p25 形成复合物时，CDK5 可与 HDAC1 结合。p35 的肉豆蔻酰化修饰促进 CDK5 与细胞膜的结合。p35 和 p35 两种亚型均与 β-catenin/CTNNB1 相互作用。与δ-catenin/CTNND2 和 APEX1 相互作用。与神经元中的 P53/TP53 相互作用。与 EPHA4 相互作用；可能介导 EPHA4 激活 NGEF。与 PTK2/FAK1 相互作用 (基于相似性)。p35/CDK5 复合物与 CLOCK 相互作用。与 HTR6 相互作用 (基于相似性)。 Cytoplasm; Nucleus; Cell membrane; Peripheral membrane protein; Perikaryon; Cell projection, lamellipodium; Cell projection, growth cone; Postsynaptic density; Synapse; Nucleus
Tissue_specificity:Widely expressed (PubMed:17009320, PubMed:19693690) . Accumulates in cortical neurons (protein level) (PubMed:17009320) ; expressed in the testes, skeletal muscle, colon, bone marrow, and ovaries.
Proline-directed serine/threonine-protein kinase essential for neuronal cell cycle arrest and differentiation and may be involved in apoptotic cell death in neuronal diseases by triggering abortive cell cycle re-entry. Interacts with D1 and D3-type G1 cyclins. Phosphorylates SRC, NOS3, VIM/vimentin, p35/CDK5R1, MEF2A, SIPA1L1, SH3GLB1, PXN, PAK1, MCAM/MUC18, SEPT5, SYN1, DNM1, AMPH, SYNJ1, CDK16, RAC1, RHOA, CDC42, TONEBP/NFAT5, MAPT/TAU, MAP1B, histone H1, p53/TP53, HDAC1, APEX1, PTK2/FAK1, huntingtin/HTT, ATM, MAP2, NEFH and NEFM. Regulates several neuronal development and physiological processes including neuronal survival, migration and differentiation, axonal and neurite growth, synaptogenesis, oligodendrocyte differentiation, synaptic plasticity and neurotransmission, by phosphorylating key proteins. Negatively regulates the CACNA1B/CAV2.2 -mediated Ca(2+) release probability at hippocampal neuronal soma and synaptic terminals (By similarity). Activated by interaction with CDK5R1 (p35) and CDK5R2 (p39), especially in postmitotic neurons, and promotes CDK5R1 (p35) expression in an autostimulation loop. Phosphorylates many downstream substrates such as Rho and Ras family small GTPases (e.g. PAK1, RAC1, RHOA, CDC42) or microtubule-binding proteins (e.g. MAPT/TAU, MAP2, MAP1B), and modulates actin dynamics to regulate neurite growth and/or spine morphogenesis. Also phosphorylates exocytosis associated proteins such as MCAM/MUC18, SEPT5, SYN1, and CDK16/PCTAIRE1 as well as endocytosis associated proteins such as DNM1, AMPH and SYNJ1 at synaptic terminals. In the mature central nervous system (CNS), regulates neurotransmitter movements by phosphorylating substrates associated with neurotransmitter release and synapse plasticity; synaptic vesicle exocytosis, vesicles fusion with the presynaptic membrane, and endocytosis. Promotes cell survival by activating anti-apoptotic proteins BCL2 and STAT3, and negatively regulating of JNK3/MAPK10 activity. Phosphorylation of p53/TP53 in response to genotoxic and oxidative stresses enhances its stabilization by preventing ubiquitin ligase-mediated proteasomal degradation, and induces transactivation of p53/TP53 target genes, thus regulating apoptosis. Phosphorylation of p35/CDK5R1 enhances its stabilization by preventing calpain-mediated proteolysis producing p25/CDK5R1 and avoiding ubiquitin ligase-mediated proteasomal degradation. During aberrant cell-cycle activity and DNA damage, p25/CDK5 activity elicits cell-cycle activity and double-strand DNA breaks that precedes neuronal death by deregulating HDAC1. DNA damage triggered phosphorylation of huntingtin/HTT in nuclei of neurons protects neurons against polyglutamine expansion as well as DNA damage mediated toxicity. Phosphorylation of PXN reduces its interaction with PTK2/FAK1 in matrix-cell focal adhesions (MCFA) during oligodendrocytes (OLs) differentiation. Negative regulator of Wnt/beta-catenin signaling pathway. Activator of the GAIT (IFN-gamma-activated inhibitor of translation) pathway, which suppresses expression of a post-transcriptional regulon of proinflammatory genes in myeloid cells; phosphorylates the linker domain of glutamyl-prolyl tRNA synthetase (EPRS) in a IFN-gamma-dependent manner, the initial event in assembly of the GAIT complex. Phosphorylation of SH3GLB1 is required for autophagy induction in starved neurons. Phosphorylation of TONEBP/NFAT5 in response to osmotic stress mediates its rapid nuclear localization. MEF2 is inactivated by phosphorylation in nucleus in response to neurotoxin, thus leading to neuronal apoptosis. APEX1 AP-endodeoxyribonuclease is repressed by phosphorylation, resulting in accumulation of DNA damage and contributing to neuronal death. NOS3 phosphorylation down regulates NOS3-derived nitrite (NO) levels. SRC phosphorylation mediates its ubiquitin-dependent degradation and thus leads to cytoskeletal reorganization. May regulate endothelial cell migration and angiogenesis via the modulation of lamellipodia formation. Involved in dendritic spine morphogenesis by mediating the EFNA1-EPHA4 signaling. The complex p35/CDK5 participates in the regulation of the circadian clock by modulating the function of CLOCK protein: phosphorylates CLOCK at 'Thr-451' and 'Thr-461' and regulates the transcriptional activity of the CLOCK-BMAL1 heterodimer in association with altered stability and subcellular distribution Q00535 has 2 isomers: Q00535-1: 33304 Da (predicted); Q00535-2: 29544 Da (predicted).
Phosphorylation on Tyr-15 by ABL1 and FYN, and on Ser-159 by casein kinase 1 promotes kinase activity. By contrast, phosphorylation at Thr-14 inhibits activity;Phosphorylation at Ser-159 i
Subcellular Localization：Cell membrane, Synapse
Expression：
Tissue specificity
|
Powered by Bioz
